top of page


ANI Pharmaceuticals launches $560 million recommended offer to acquire Egetis Therapeutics
ANI Pharmaceuticals has launched a recommended cash offer valued at approximately $560 million for Swedish rare-disease specialist Egetis Therapeutics, seeking to add the approved MCT8-deficiency treatment Emcitate to its portfolio.

nuaxia
Nov 62 min read


EU Council formally adopts sweeping pharmaceutical legislation reform
The Council has formally adopted its position on the EU pharmaceutical package, moving the bloc's largest overhaul of medicines legislation in decades toward its final legislative stages.

nuaxia
Sep 292 min read
bottom of page